Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/19/2012USRE43481 Diazepan derivatives or salts thereof
06/19/2012US8203019 Halofenate in a crystalline solid form; Type 2 diabetes, hyperlipidemia
06/19/2012US8203016 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents
06/19/2012US8203011 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same
06/19/2012US8203003 4-fluoropyrrolidine-2-carbonyl fluoride compounds and their preparative methods
06/19/2012US8203001 Chemical compounds
06/19/2012US8203000 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
06/19/2012US8202999 Compounds for inflammation and immune-related uses
06/19/2012US8202996 Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
06/19/2012US8202993 Spiro-piperidine derivatives
06/19/2012US8202984 Glucopyranoside compound
06/19/2012US8202982 Methods of obtaining active antisense compounds
06/19/2012US8202980 Antisense oligonucleotide for use in prevention and treatment of viral and tumor disorders; gene expression inhibition; RNA interference
06/19/2012US8202974 Synthetic RNA-based agonists of TLR7
06/19/2012US8202911 Migrastatin analog compositions and uses thereof
06/19/2012US8202910 Compositions and methods for treatment of infectious disease
06/19/2012US8202909 Method for treating central nervous system disorders
06/19/2012US8202908 D-aspartic acid supplement
06/19/2012US8202907 Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders
06/19/2012US8202906 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy
06/19/2012US8202905 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof
06/19/2012US8202903 Use of aminaphtone for the preparation of a medicament for treating arteriopathies
06/19/2012US8202902 Bivalent SMAC mimetics and the uses thereof
06/19/2012US8202900 Method for stabilizing quercetin
06/19/2012US8202899 Pyrazole urea derivatives used as kinase inhibitors
06/19/2012US8202898 Pharmaceutical composition
06/19/2012US8202897 pharmaceutically acceptable salt, solvate or polymorph for disease therapy
06/19/2012US8202896 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
06/19/2012US8202895 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
06/19/2012US8202893 Cannabinergic lipid ligands
06/19/2012US8202892 Advanced glycation end products as active ingredients
06/19/2012US8202891 Quaternary ammonium compounds useful as muscarinic receptor antagonists
06/19/2012US8202890 Pest control agent
06/19/2012US8202889 Inhibitors of bacterial IMPDH
06/19/2012US8202888 Piperidine sulphonamide derivatives
06/19/2012US8202887 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
06/19/2012US8202886 Small molecule E2F inhibitor
06/19/2012US8202885 Bridged six-membered ring compounds
06/19/2012US8202884 Treatment of type 2 diabetes
06/19/2012US8202883 Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases
06/19/2012US8202882 5-cyanothienopyridines for the treatment of tumours
06/19/2012US8202881 JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
06/19/2012US8202880 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors
06/19/2012US8202879 Quinazoline derivatives having tyrosine kinase inhibitory activity
06/19/2012US8202878 Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid
06/19/2012US8202876 Compounds and compositions as protein kinase inhibitors
06/19/2012US8202874 Substituted N-oxide pyrazine derivatives
06/19/2012US8202873 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists
06/19/2012US8202872 Pyrazole derivatives as sigma receptor inhibitors
06/19/2012US8202871 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
06/19/2012US8202870 Substituted oxindole derivatives, medicaments containing the latter and use thereof
06/19/2012US8202869 Method of treating an anxiety disorder
06/19/2012US8202868 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
06/19/2012US8202867 Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide
06/19/2012US8202866 Ortho-aminoanilides for the treatment of cancer
06/19/2012US8202865 Oxadiazole derivatives
06/19/2012US8202864 Compounds
06/19/2012US8202863 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease
06/19/2012US8202862 Substituted piperidines
06/19/2012US8202861 Compositions useful as inhibitors of voltage-gated sodium channels
06/19/2012US8202860 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
06/19/2012US8202859 Heterocyclic sulfonamides
06/19/2012US8202858 Vasopressin V1a antagonists
06/19/2012US8202857 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1
06/19/2012US8202856 Triazole oxadiazoles derivatives
06/19/2012US8202854 Heterocyclic aspartyl protease inhibitors
06/19/2012US8202853 Convenience kit for eyelid treatment
06/19/2012US8202852 Creatine phosphate analog prodrugs, compositions and uses thereof
06/19/2012US8202850 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
06/19/2012US8202849 Methods and compositions for the inhibition of Stat5 in prostate cancer cells
06/19/2012US8202847 Mutant human CD80 and compositions for and methods of making and using the same
06/19/2012US8202846 Methods and compositions for RNA interference
06/19/2012US8202845 Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification
06/19/2012US8202844 Indole antiviral compositions and methods
06/19/2012US8202843 Macrocyclic compounds and methods of making and using the same
06/19/2012US8202842 Inhibition of cholera toxins by galatooligosaccharides (GOS)
06/19/2012US8202834 Fat regulation
06/19/2012US8202833 Composition containing biocompatible polymerization accelerator and polymerizable material
06/19/2012US8202724 Methods of controlling proliferation and differentiation of stem and progenitor cells
06/19/2012US8202695 Compositions, methods and kits for repressing virulence in gram positive bacteria
06/19/2012US8202550 Compositions for intranasal administration
06/19/2012US8202547 Citrate-based dialysate chemical formulations
06/19/2012US8202546 Nutritional supplement for use under physiologically stressful conditions
06/19/2012US8202540 Method for controlled production of ultrafine microparticles and nanoparticles
06/19/2012US8202537 Modified release formulations containing drug-ion exchange resin complexes
06/19/2012US8202517 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
06/19/2012US8202513 Aryl potassium channel blockers and uses thereof
06/19/2012US8202512 Metabolic uncoupling therapy
06/19/2012US8202242 administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone
06/19/2012CA2685219C Diazaquinolones that inhibit prolyl hydroxylase activity
06/19/2012CA2684169C Smac mimetic dimers and trimers useful as anti-cancer agents
06/19/2012CA2683939C Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
06/19/2012CA2671236C Novel derivatives of cycloalkyl-substituted benzothiadiazines, process for their preparation and pharmaceutical compositions containing them
06/19/2012CA2648985C Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity
06/19/2012CA2626558C Pharmaceutical composition having reduced abuse potential
06/19/2012CA2613303C An oxime derivative for use as a glucokinase activator
06/19/2012CA2607151C Hiv integrase inhibitors
06/19/2012CA2599754C Use of interleukin 17e for the treatment of cancer
06/19/2012CA2559699C Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
06/19/2012CA2559302C 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
1 ... 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 ... 7860